Breaking News

Financial Report: AbbVie

April 26, 2013

Humira sales up 16% in first reporting quarter

1Q Revenues: $4.3 billion (+4%)
1Q Earnings: $968 million (+10%)
Comments: Growth was driven by Humira sales in the U.S. and internationally, up 16% to $2.2 billion. Synagis sales were $345 million, down 1%. AndroGel sales were up 3% to $240 million. TriCor/Trilipix sales were down 50% to $128 million due to the loss of exclusivity. Lupron sales were down 9% to $181 million.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks